.September 6, 2024 Friday 12:36 PM

Morgan Stanley analysts reaffirmed their Equalweight rating and $60 price target on Solventum (NYSE:SOLV) stock. They praised the company’s efforts to revamp its corporate culture post-spin-off, resulting in increased employee engagement and leadership support.

Solventum aims to enhance agility, boost R&D efficiency, and focus on healthcare. Analysts noted ongoing discussions on balancing growth reinvestment and margin preservation, with a strong emphasis on targeting high-growth markets and increasing revenue.

Despite potential uncertainty in 2025 EPS forecasts due to strategic changes, analysts favor aggressive investment for long-term growth over conservative approaches.